|
Nasal Vaccines Market |
Market Overview:
Nasal vaccines are a type of immunization administered through the nasal route.
They offer numerous advantages such as ease of administration, painless
delivery, and stimulation of both systemic and mucosal immune responses. The need
for nasal vaccines is associated with the increasing prevalence of infectious
diseases and the growing demand for needle-free immunization methods. Nasal
vaccines have been proven effective against various diseases such as influenza,
measles, and polio. The market for nasal vaccines is expected to witness
significant growth due to their ability to provide long-lasting immunity and
reduce the risk of disease transmission.
Market Key Trends:
One key trend in the Nasal vaccine market is the rising adoption of intranasal
delivery systems. Nasal vaccines provide several benefits compared to
traditional injectable vaccines, such as improved patient compliance, reduced
pain and fear associated with injections, and the potential to elicit a
stronger immune response. Intranasal delivery systems also enable the delivery
of vaccines directly to the mucosal surfaces of the respiratory tract, where
many infectious pathogens enter the body.
The global Nasal
Vaccines Market Demand is estimated to be valued at US$416.8 million in 2023 and is
expected to exhibit a CAGR of 8.6% over
the forecast period 2023-2030, according to a new report published by Coherent
Market Insights.
Segment Analysis:
The nasal vaccines market can be segmented based on type, application, and
end-user. Based on type, the market can be divided into inactivated vaccines,
live attenuated vaccines, and subunit vaccines. Among these, live attenuated
vaccines dominate the market due to their ability to mimic natural infection
and provide long-lasting immunity. These vaccines contain weakened or modified
forms of the pathogen and have been proven effective against various diseases
such as influenza and measles. Due to their higher efficacy, live attenuated
vaccines are preferred over other types.
Key Takeaways:
The global nasal vaccines market is expected to witness high growth, exhibiting
a CAGR of 8.6% over the forecast period. This growth can be attributed to
several factors, including the increasing prevalence of infectious diseases,
rising awareness about vaccination, and advancements in vaccine technology. The
market is expected to reach US$ 416.8 million in 2023.
In terms of regional analysis, North America is the fastest-growing and
dominating region in the nasal vaccines market. This can be attributed to the
presence of key market players, well-established healthcare infrastructure, and
high healthcare expenditure in the region. Additionally, the increasing
incidence of respiratory diseases and the growing demand for preventive
healthcare are driving the market growth in North America.
Key players operating in the nasal vaccines market include AstraZeneca,
GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., Sanofi
Pasteur SA, Johnson & Johnson Services, Inc., Sinovac Biotech Ltd., Bharat
Biotech International Limited, Altimmune, Inc., BiondVax Pharmaceuticals Ltd.,
FluGen Inc., Vaxart, Inc., Intravacc, Ennaid Therapeutics, LLC, and Gamma
Vaccines Pty Ltd. These key players are focusing on strategic partnerships,
mergers and acquisitions, and product launches to strengthen their market
presence and expand their product portfolio.
Read
More: https://www.newsstatix.com/nasal-vaccines-market-growing-demand-for-non-invasive-vaccination-drives-market-growth/
Comments
Post a Comment